Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: MATRISOME BIO, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2025-09-15 to 2026-09-14
Current total value of award: $354456
Description: NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC)